FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to immunology. There are presented the antibodies that bind to the P-selectin glycoprotein ligand-1 (PSGL-1), as well as methods for stimulating the death of activated T-cells and simulating T-cell immune response in a patient by the use of the antibodies under the invention, and pharmaceutical compositions containing the antibodies under the invention. There are also disclosed nucleic acids, expression vectors and host cells for producing the antibodies under the invention.
EFFECT: invention may can find further application in therapy of the PSGL-1 associated diseases.
35 cl, 4 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| P-SELECTIN ANTIBODIES AND METHODS FOR THEIR USING AND IDENTIFICATION | 2011 |
|
RU2603097C2 |
| P-SELECTIN GLYCOPROTEIN LIGAND 1 MODULATORS | 2004 |
|
RU2407539C2 |
| ANTI-PSGL-1-ANTIBODIES AND THEIR APPLICATION | 2012 |
|
RU2650817C2 |
| TETRAVALENT ANTIBODIES TO PSGL-1 AND THEIR APPLICATIONS | 2017 |
|
RU2766000C2 |
| RECOMBINANT ANTIBODY IL4 USED FOR TREATMENT OF DISORDERS ASSOCIATED WITH FUNCTION OF IL4 | 1994 |
|
RU2162711C2 |
| HUMANIZED ANTIBODIES TO CTLA4 | 2012 |
|
RU2629768C2 |
| ANTIBODIES TO INTERLEUKIN-1ALPHA, AND APPLICATION METHODS THEREOF | 2013 |
|
RU2666915C2 |
| SINGLE-DOMAIN ANTIBODY AND DERIVATIVES THEREOF TO LIGAND-1 PROTEIN OF PROGRAMMED CELL DEATH (PDLI) | 2016 |
|
RU2715595C2 |
| ANTIBODIES TO INTERLEUKIN-1α, AND ITS APPLICATION METHODS | 2009 |
|
RU2498998C2 |
| ANTIBODY AGAINST LAG-3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR PHARMACEUTICAL APPLICATION | 2017 |
|
RU2757813C2 |
